Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

VTRS · Q3 2025 Earnings

Viatris

Reported November 6, 2025

30-second summary

Viatris raised and narrowed FY2025 guidance on revenue, adjusted EPS, and adjusted EBITDA — a sharper move than last quarter's "top half of range" hedge — while Q3 revenue grew 0.2% YoY to $3.76B, the first positive print this year. Management explicitly attributed the raises to foreign exchange and share repurchases rather than underlying operating outperformance. The story is mix: Greater China +9% and Emerging Markets +7% are now visibly carrying the consolidated number, while Generics (-6%) and JANZ (-9%) remain Indore-constrained but improving sequentially. Operating cash flow high end was trimmed $50M to $2.45B while the FCF range was narrowed with the midpoint held at $2.0B — worth watching but not flagged by management as a working-capital or capex signal.

Headline numbers

EPS

Q3 FY2025

$0.67

Revenue

Q3 FY2025

$3.76B

+0.2% YoY

Gross margin

Q3 FY2025

36.5%

Free cash flow

Q3 FY2025

$0.66B

Operating margin

Q3 FY2025

4.8%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$3.76B	+0.2%	$3.58B	+5.0%
EPS	$0.67	—	$0.62	+8.1%
Gross margin	36.5%	—	37.2%	-70bps
Operating margin	4.8%	—	6.5%	-170bps
Free cash flow	$0.66B	—	$0.17B	+294.5%

Guidance

FY2025 guidance raised and narrowed across revenue, EPS, and EBITDA; operating cash flow high end modestly lowered.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY 2025	$13.5 billion to $14.0 billion	$13.9 billion to $14.3 billion	+$0.4 billion low end, +$0.3 billion high end	Raised
Adjusted EPS	FY 2025	$2.16 to $2.30	$2.25 to $2.35	+$0.09 low end, +$0.05 high end	Raised
Adjusted EBITDA	FY 2025	$3.89 billion to $4.19 billion	$4.0 billion to $4.2 billion	+$0.11 billion low end, +$0.01 billion high end	Raised
Operating Cash Flow	FY 2025	$2.2 billion to $2.5 billion	$2.2 billion to $2.45 billion	-$0.05 billion high end	Lowered

Reaffirmed unchanged this quarter: Free Cash Flow ($1.85 billion to $2.15 billion)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Brands	$2.437B	+1.0%
Generics	$1.311B	-6.0%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Developed Markets	$2.256B	-5.0%
Greater China	$0.615B	+9.0%
JANZ	$0.306B	-9.0%
Emerging Markets	$0.57B	+7.0%
Adjusted EBITDA	$1,154.6 million	—
Adjusted Gross Margin	56.0%	—
Adjusted EPS	$0.67	—
Operating Cash Flow	$744.9 million	—
New Product Revenues	~$100 million	—
Capital Returns YTD	$920 million	—
Share Repurchases YTD	$500 million	—

Management tone

Defense → Pipeline pivot → "Top half" hedge → Raised and narrowed.

Last quarter management hedged with "top half of range." This quarter they raised the range itself and narrowed it, though they were explicit that the raise was "primarily driven by foreign exchange and share repurchases" rather than operational beat. The qualitative framing shifted to "remain on track to deliver on all 2025 financial commitments."

Indore moved from "we requested an FDA meeting" (Q2) to "initial remediation activities are substantially complete" with redundancy built across other sites and third-party vendors. The press release frames the remaining variable as FDA re-inspection scheduling, not Viatris's own remediation work — a meaningful narrowing of what can still go wrong. The Generics improvement from -9% to -6% YoY is the early validation.

Meloxicam graduated again — from "promising pipeline asset" in Q2 to cornerstone product this quarter, with management broadly framing it as a multi-year contributor and reaffirming year-end NDA submission (with potential government-shutdown delays the only caveat).

The strategic review evolved from "significant cost savings coming" (Q2) to a transformational multi-year program with explicit reinvestment: "meaningful net cost savings over a multi-year period, while also being able to reinvest a portion of the savings back into the business to fund future growth." Management deferred the granular numbers to a Q1 2026 investor event — not the Q3 disclosure last quarter's call had pointed to. That is a partial slip on the prior commitment, even if the strategic direction has hardened.

Greater China shifted from "stabilizing market" framing in earlier quarters to a definitive growth driver: two consecutive quarters of +9% growth and management explicitly calling out "very strong third quarter" and YTD performance. This is the offset that makes the Developed Markets -5% absorbable.

Recurring themes management leaned on this quarter:

Pipeline momentum with multiple late-stage assets approaching approvalIndoor facility remediation complete; supply chain redundancy builtEnterprise-wide strategic review targeting multi-year cost savings with reinvestmentStrong performance in emerging markets and China offsetting North America headwindsCapital allocation balanced between shareholder returns and growth-oriented M&ACommercial readiness for multiple launches in 2026 (meloxicam, estrogen patch, presbyopia)

Risks management surfaced:

Indoor re-inspection timing discretionary with FDA; uncertain resolution timing for import alertNorth America competitive pressures and potential loss of exclusivity for Ameteza in JapanForeign exchange headwinds from favorable 2025 tailwinds not expected to repeat in 2026U.S. government shutdown potential delays to NDA submissionsPricing and payer access challenges for newly launched innovative products

Answers to last quarter's watch list

Indore FDA re-inspection timing. Management says remediation is "substantially complete" and they "recently met with the FDA to review progress and discuss potential timing for re-inspection." No specific date secured — timing remains at FDA discretion. Generics improved to -6% from -9%, suggesting partial operational recovery is already flowing through.

Continue monitoring

Strategic review cost-savings figure. No specific dollar number disclosed this quarter. Management instead committed to a Q1 2026 investor event for "strategic and financial outlook" — pushing the granular disclosure one quarter past what Q2 commentary implied. The qualitative framing hardened (multi-year savings with reinvestment, majority dropping to the bottom line) but the number didn't come.

Not resolved

New product revenue cadence. Q3 came in at ~$100M, up from $79M in Q2, putting YTD at ~$258M. Still requires a $200M+ Q4 to hit the $450M+ historical run-rate, which is plausible but not yet evidenced. Cadence is improving, not yet sufficient.

Continue monitoring

Meloxicam filing. Management reaffirmed year-end NDA submission, with the only caveat being potential delays from the U.S. government shutdown. Beyond the filing, management put a loose peak-sales anchor (~$500M "in the right range") and elevated meloxicam to a multi-year contributor.

Resolved positively

Eye care revenue disclosure. No specific revenue base or growth target disclosed for the eye care franchise this quarter; management deferred the strategic articulation to the Q1 2026 investor event. The "meaningful contributor" language continues without numerical anchoring.

Not resolved

What to watch into next quarter

Q4 operating cash flow delivery. Watch whether Q4 OCF lands above ~$700M (required to hit midpoint $2.325B). Management framed the trim as housekeeping, not stress — a meaningful Q4 miss would change that read.

Q1 2026 investor event substance. Management has now twice deferred the strategic review cost-savings number. A specific multi-year dollar target plus reinvestment split is the minimum required; Smith's Q&A signal that the majority drops to the bottom line raises the bar on disclosure quality.

Indore FDA re-inspection date. Whether a date is secured by the Q4 print determines if Generics returns to positive YoY in 2026. Generics at -6% (vs -9% in Q2) suggests partial recovery is happening anyway, but full reversal needs the import alert lifted.

Meloxicam NDA submission by year-end. Government shutdown was flagged as the only risk. Slippage into 2026 delays the 2026 launch narrative meaningfully.

Q4 new product revenue. ~$200M needed in Q4 alone to hit historical $450M+ annual cadence. A sub-$150M print would force a reset of the new-product contribution thesis for 2026.

Sources

Viatris Q3 2025 Earnings Release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1792044/000179204425000042/exhibit991-3q25earningsrel.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.